ArticleCommunications medicine2025
Lifetime risk, sex and age differences in annual incidence of ocular motor cranial nerve palsy in Japan for 2019.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nationwide Multicenter Survey of Severe Complications of Strabismus Surgery in Japan: Japanese Strabismus Surgery Study.Ophthalmology science · 2026Article
- Outcomes of Strabismus Surgery in Patients with Cranial Nerve Palsy.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundWe aimed to demonstrate the incidence and subtype proportions of ocular motor cranial nerve palsy (OMCNP) by age group and sex, and to estimate the associated lifetime risks in the Japanese population.
methodsThis nationwide, population-based, cross-sectional cohort study utilized data from the National Database of Health Insurance Claims and Specific Health Checkups of Japan, provided by the Ministry of Health, Labour and Welfare, covering almost all (≥95%) claims. We identified newly diagnosed OMCNP cases (oculomotor, trochlear, or abducens palsy) between January 1 and December 31, 2019, separated by sex and age category (5-year steps). We calculated the incidence rate as the proportion relative to the Japanese population, and calculated the lifetime risk. Furthermore, we calculated the age-standardized incidence rate and lifetime risk according to the world population distribution.
resultsThe crude incidence rate of OMCNP is 17.36 (oculomotor palsy, 6.62 [38.1%]; trochlear palsy, 2.61 [15.0%]; abducens palsy, 8.14 [46.9%]) per 100,000 person-years. The incidence rate increases with age and is higher in men than in women (19.91 vs. 14.96). The lifetime risks of oculomotor, trochlear, and abducens palsies are 0.50%, 0.19%, and 0.61%, respectively. The age-standardized incidence rates of oculomotor, trochlear, and abducens palsies are 3.25 (lifetime risk, 0.35%), 1.28 (lifetime risk, 0.13%), and 4.60 (lifetime risk, 0.45%) per 100,000 person-years, respectively.
conclusionsThis nationwide study of >100 million people reveals that OMCNP incidence increases with age and is higher in men. Approximately one in 100 individuals is affected in their lifetime. Our comprehensive analysis of OMCNP demographics provides important information for addressing healthcare, particularly for older people, from social and public health perspectives.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.